Keeping, Sam <br/><br/>
Pembrolizumab versus the standard of care for relapsed and refractory classical Hodgkin's lymphoma progressing after brentuximab vedotin: an indirect treatment comparison.  [electronic resource] 

 -  Expert review of hematology  06 2018 
 - 503-511 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Systematic Review 
<br/><br/><label>ISSN: </label>1747-4094 
<br/><br/><label>Standard No.: </label>10.1080/17474086.2018.1475226  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal, Humanized--adverse effects<br/>Brentuximab Vedotin<br/>Female<br/>Hodgkin Disease--drug therapy<br/>Humans<br/>Immunoconjugates--adverse effects<br/>Male